Floatz logo

Autologous Cytomegalovirus-Specific Cytotoxic T-Lymphocytes

Malignant Glioma

M.D. Anderson Cancer CenterCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

109 Active assets in the Malignant Glioma cohort.

Asset / SponsorPhaseRating
Irinotecan
Kailin Yang, MD, PhD
Phase 2BB
Marizomib
Aadi Bioscience, Inc.
Phase 2BB
Valaciclovir
Trogenix ltd
Phase 2BB
Valproic Acid
Virginia Commonwealth University
Phase 2BB
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE
Oblato, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Autologous Cytomegalovirus-Specific Cytotoxic T-Lymphocytes is also rated in:

brain neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
gliosarcomaDormant
CCC
Indicative ·
48 / 100
View asset →
glioblastomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →